Search
Kava
go.drugbank.com/drugs/DB01322ApprovedInvestigationalNutraceuticalWithdrawnCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesQuinupristin
go.drugbank.com/drugs/DB01369ApprovedQuinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
17alpha-methyl-4-hydroxynandrolone
go.drugbank.com/drugs/DB01540ExperimentalIllicit17alpha-methyl-4-hydroxynandrolone is a schedule 3 anabolic steroid.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
go.drugbank.com/drugs/DB01562ExperimentalIllicit1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP) is a synthetic analogue of meperidine. It is sold as a "synthetic heroin."
Methyl-1-testosterone
go.drugbank.com/drugs/DB01572ExperimentalIllicitIt is a derivative of 1-testosterone with a methyl group in the carbon 17. Methyl-1-testosterone is considered a prohibited doping substance. … Methyl-1-testosterone is a synthetic and orally active anabolic–androgenic steroid (AAS) which was never marketed for medical use.
5-fluorouridine
go.drugbank.com/drugs/DB01629InvestigationalThese are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase. … 5-fluorouridine is also known as FUrd, 5-Fluorouracil 1-beta-D-ribofuranoside, 5-Fur, or 5-Fluoro-uridine. 5-fluorouridine is a solid.
AZD-9684
go.drugbank.com/drugs/DB05712ExperimentalAZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.
ALKS 29
go.drugbank.com/drugs/DB05723ExperimentalALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Strontium malonate
go.drugbank.com/drugs/DB05732InvestigationalStrontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.